These mechanisms seem to be, at least in part, mediated through the modulation of the GH/IGF-1/insulin system
In rare cases, some patients may experience side effects as the result of allergic reactions or sensitivity
Adverse effects include muscarinic symptoms (e.g., gastrointestinal upset, increased secretions) and nicotinic effects (e.g., muscle cramps, fasciculations, weakness)
Follow our page for more such updates: News Source: #CagriSema #NovoNordisk #Obesity #ObesityTreatment #WeightLoss #GLP1 #Incretins #MetabolicHealth #Cardiometabolic #Phase3 #ClinicalTrials #REDEFINE4 #DrugDevelopment #PharmaInnovation To view or add a comment, sign in Novo Nordisk's CagriSema Delivers 23% Weight Loss but Misses Non-Inferiority vs Tirzepatide in REDEFINE-4 Novo Nordisk reported topline results from the Phase 3 REDEFINE-4 trial evaluating CagriSema (cagrilintide + semaglutide) in obesity
Within a month of taking Guttides, I noticed a dramatic reduction in bloating and discomfort